'''Inogatran''' ([[International nonproprietary name|INN]])<ref name="INN">{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 35 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL35.pdf | publisher = World Health Organization | accessdate = 2 December 2016 | page = 13}}</ref> is a low [[molecular weight]] peptidomimetic [[Direct thrombin inhibitor|thrombin inhibitor]]. Inogatran was developed for the potential treatment of [[Artery|arterial]] and [[Vein|venous]] [[Thrombosis|thrombotic]] diseases.<ref>{{cite journal | last1 = Teger-Nilsson | first1 = AC | last2 = Bylund | first2 = R | last3 = Gustafsson | first3 = D | last4 = Gyzander | first4 = E | last5 = Eriksson | first5 = U | title = ''In Vitro'' Effects of Inogatran, a Selective Low Molecular Weight Thrombin Inhibitor | journal = [[Thrombosis Research]] | date = January 1997 | volume = 85 | issue = 2 | pages = 133â€“45 | doi = 10.1016/s0049-3848(96)00230-7 | pmid = 9058487}}</ref>
